Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lisinopril dihydrate, quantity: 5.44 mg - tablet - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; maize starch; magnesium stearate; croscarmellose sodium; iron oxide red - 1.hypertension: lisinopril is indicated for the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. 2. congestive heart failure: lisinopril is also indicated for the treatment of heart failure. in such patients, it is recommended that lisinopril be administered together with a diuretic. 3. acute myocardial infarction: lisinopril is indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - sumatriptan, quantity: 100 mg (equivalent: sumatriptan succinate, qty 140 mg) - tablet, film coated - excipient ingredients: magnesium stearate; calcium hydrogen phosphate; sodium bicarbonate; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; hypromellose; triacetin - indicated for the acute relief of migraine attacks with or without aura. there is no information available on the use of imigran in the treatment of basilar or hemiplegic migraine.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - sumatriptan succinate, quantity: 70 mg (equivalent: sumatriptan, qty 50 mg) - tablet, film coated - excipient ingredients: sodium bicarbonate; calcium hydrogen phosphate; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; hypromellose; triacetin; iron oxide red - indicated for the acute relief of migraine attacks with or without aura. there is no information available on the use of imigran in the treatment of basilar or hemiplegic migraine.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lisinopril dihydrate, quantity: 21.78 mg (equivalent: lisinopril, qty 20 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; maize starch; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica - hypertension: treatment of hypertension. lisinopril may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: treatment of heart failure. in such patients, it is recommended that lisinopril be administered together with a diuretic. acute myocardial infarction: treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lisinopril dihydrate, quantity: 10.89 mg (equivalent: lisinopril, qty 10 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; maize starch; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica - hypertension: treatment of hypertension. lisinopril may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: treatment of heart failure. in such patients, it is recommended that lisinopril be administered together with a diuretic. acute myocardial infarction: treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lisinopril dihydrate, quantity: 5.445 mg (equivalent: lisinopril, qty 5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; maize starch; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica - hypertension: treatment of hypertension. lisinopril may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: treatment of heart failure. in such patients, it is recommended that lisinopril be administered together with a diuretic. acute myocardial infarction: treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fosinopril sodium, quantity: 20 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; crospovidone; povidone; glyceryl behenate - hypertension: treatment of mild to moderate hypertension. fosinopril is effectine alone as initial therapy or in combination with other antihypertensive agents. the antihypertensive effects of fosinopril and diuretics used concomitantly are approximately additive. data have not been provided to support the use of fosinopril in severe or renovascular hypertension. heart failure: management of heart failure when added to conventional therapy, including diuretics.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fosinopril sodium, quantity: 10 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; crospovidone; povidone; glyceryl behenate - hypertension: treatment of mild to moderate hypertension. fosinopril is effectine alone as initial therapy or in combination with other antihypertensive agents. the antihypertensive effects of fosinopril and diuretics used concomitantly are approximately additive. data have not been provided to support the use of fosinopril in severe or renovascular hypertension. heart failure: management of heart failure when added to conventional therapy, including diuretics.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - bromocriptine mesilate, quantity: 2.87 mg (equivalent: bromocriptine, qty 2.5 mg) - tablet, uncoated - excipient ingredients: maleic acid; colloidal anhydrous silica; magnesium stearate; maize starch; lactose monohydrate; disodium edetate - prevention of onset of lactation in the puerperium for clearly defined medical reasons. therapy should be continued for 14 days to prevent rebound lactation. parlodel should not be used to suppress established lactation. treatment of hyperprolactinaemia where surgery and/or radiotherapy are not indicated or have already been used with incomplete resolution. precautions should be taken to ensure that the hyperprolactinaemia is not due to severe primary hypothyroidism. where the cause of hyperprolactinaemia is a prolactin-secreting microadenoma or macroadenoma, parlodel is indicated for conservative treatment; prior to surgery in order to reduce tumour size and to facilitate removal; after surgery if prolactin level is still elevated. adjunctive therapy in the management of acromegaly when: (1) the patient refuses surgery and/or radiotherapy; (2) surgery and/or radiotherapy has been unsuccessful or full effects are not expected for some months; (3) a manifestation of the acromegaly needs to be brought under con

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - sumatriptan succinate, quantity: 70 mg (equivalent: sumatriptan, qty 50 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; hypromellose; macrogol 8000; triacetin; iron oxide yellow; iron oxide red; polydextrose - for the acute relief of migraine in patients who have a stable, well-established pattern of symptoms.